Physician profile
Antikkumar Patel
NPI 1821738774
$1,404.80
in general payments reported to CMS, 2019-2025
16 companies · $835 in 2025
The $835 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $112 · 2024: $458 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350 · Education: $54.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.84 |
| Education | $54.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $282.18 | 2024 | Trevo, Target, Surpass Evolve |
| Penumbra, INC. | $244.82 | 2025 | Penumbra System |
| Ucb, INC. | $230.07 | 2024-2025 | Fintepla |
| Merz Pharmaceuticals, LLC | $162.30 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Medtronic, INC. | $94.90 | 2025 | Solitaire X |
| Teva Pharmaceuticals USA, INC. | $77.65 | 2025 | Austedo Xr |
| Abbvie INC. | $54.96 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $48.30 | 2024-2025 | Wainua |
| Neurelis, INC. | $35.20 | 2025 | Valtoco |
| Vanda Pharmaceuticals INC. | $34.88 | 2025 | Ponvory |
| Sk Life Science, INC. | $27.27 | 2023 | |
| Jazz Pharmaceuticals INC. | $26.49 | 2025 | Epidiolex |
| Pfizer INC. | $24.70 | 2025 | |
| Travere Therapeutics, INC. | $24.18 | 2023 | |
| Alexion Pharmaceuticals, INC. | $23.41 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $13.49 | 2025 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antikkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.